drugset
drugset / Trial / NCT03795272

Rucaparib Maintenance Therapy in Advanced Cervical Cancer

NCT03795272 ↗

Phase 2 Withdrawn Nordic Society of Gynaecological Oncology - Clinical Trials Unit Belgian Gynaecological Oncology Group · collabCentral and Eastern European Oncology Group · collabGCP-enhederne · collabGSO Global Clinical Research BV · collabInstitute of Cancer Research, United Kingdom · collabNorth Eastern German Society of Gynaecological Oncology · collabPGOG (Polish Gynaecologic Oncology Group) · collabPrincess Margaret Hospital, Canada · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy of PARP inhibitor, rucaparib as maintenance therapy for locally advanced cervical cancer

Timeline

Start
2019-10-01
Primary completion
2019-10-10
Completion
2019-10-10

Outcome

Outcome not reported

Stopped (Business): “Lack of financial support”

Drugs

EvaluationDrugModalityDoseRoute
Subject Rucaparib Small molecule — Oral

Indications

cervical cancer